SHARE



DUBLIN–(BUSINESS WIRE)–Feb 2, 2021–

The “Regulatory Report: Philippines CBD” report has been added to ResearchAndMarkets.com‘s offering.

Hemp is considered to be the equivalent of cannabis in the Philippines and is, therefore, a prohibited drug, carrying severe penalties for its cultivation, manufacture, sale, importation, possession and use under Republic Act No. 9165, known as the Comprehensive Dangerous Drugs Act of 2002.

Although there are some exceptions regarding hemp imports (i.e. for medical use and in some processed forms), its sale is minimal, according to a report issued by the USDA Foreign Agricultural Service.

A debate on regulating cannabis for medicinal use is on the table in the Philippines, and several bills are currently being discussed. This report provides an overview of the current regulatory regime for CBD and cannabis in the country.

Key Topics Covered:

1 Executive Summary

2 Outlook

3 Hemp Plant

4 Extracts as a Finished Product

5 Finished Products Containing CBD and Extracts

6 Import and Export Requirements

7 Medical Cannabis

8 Recreational Cannabis

9 Relevant Laws

10 Relevant Bodies

For more information about this report visit https://www.researchandmarkets.com/r/ov57oc

View source version on businesswire.com:https://www.businesswire.com/news/home/20210202005635/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD: PHILIPPINES ASIA PACIFIC

INDUSTRY KEYWORD: ALTERNATIVE MEDICINE HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 02/02/2021 07:13 AM/DISC: 02/02/2021 07:13 AM

http://www.businesswire.com/news/home/20210202005635/en

Copyright Business Wire 2021.

0
SHARE

Leave a Reply